The company focuses on addressing the global smoking and nicotine dependence epidemic through cytisinicline, having completed two Phase III studies for smoking cessation and one Phase II study for vaping cessation. Achieve maintains license and supply agreements with Sopharma AD and University of Bristol, establishing strategic partnerships for development and commercialization.
Cyborg Score Rationale
Achieve is advancing a potentially first-in-class therapy with completed Phase III trials and imminent FDA decision (June 2026). The company has demonstrated clinical efficacy and secured regulatory endorsement through expedited pathways. However, pre-commercial execution and market adoption risks remain.
Top Insights
Pivotal FDA milestone: NDA accepted for smoking cessation with PDUFA decision expected June 20, 2026, critical inflection point for valuation
Dual-indication strategy: Expanding beyond smoking cessation into e-cigarette/vaping cessation, a substantial and underserved market
First-in-class potential: Cytisinicline would be first new smoking cessation therapy in approximately two decades, offering significant commercial opportunity
Expedited regulatory pathway: FDA granted expedited review status for vaping cessation indication, recognizing unmet medical need
Named Competitors
Chantix (varenicline) — Established smoking cessation therapy, competitive standard
Bupropion-based therapies — Antidepressant used off-label for smoking cessation
Nicotine Replacement Therapies (NRT) — Over-the-counter and prescription nicotine delivery systems
Recent Developments
(January 2026) Dr. Mark Rubinstein promoted to permanent Chief Medical Officer following interim tenure
(January 2026) Board approved stock option grants for five new employees as company scales ahead of FDA decision
(September 2025) FDA accepted NDA for smoking cessation with June 20, 2026 PDUFA date